By Cecilia Butini BioNTech on Monday posted a loss for the second quarter as some write-offs by its vaccine partner Pfizer lowered its gross profit share and revenue, but said it continues to...
BioNTech records loss of 190 mln euros in Q2 as covid vaccine demand wanes bignewsnetwork.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bignewsnetwork.com Daily Mail and Mail on Sunday newspapers.
BioNTech records loss of 190 mln euros in Q2 as covid vaccine demand wanes-Xinhua english.news.cn - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from english.news.cn Daily Mail and Mail on Sunday newspapers.
BioNTech records loss of 190 mln euros in Q2 as covid vaccine demand wanes hawaiitelegraph.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from hawaiitelegraph.com Daily Mail and Mail on Sunday newspapers.
BERLIN, Aug. 7 (Xinhua) -- German developer and manufacturer of active immunotherapies BioNTech on Monday posted a loss of 190 million euros (209 million U.S. dollars) in the second quarter of 2023 as demand for its COVID-19 vaccine waned.
BioNTech records loss of 190 mln euros in Q2 as covid vaccine demand wanes europesun.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from europesun.com Daily Mail and Mail on Sunday newspapers.
BioNTech’s alliance with DualityBio gives it two antibody drug conjugate (ADC) candidates, the most advanced of which is in mid-stage clinical development for solid tumors. It addresses the same target as a potential blockbuster AstraZeneca drug.
BioNTech, with its partner Pfizer, expects to begin deliveries of two omicron-adapted vaccines as soon as October in time for a fall vaccination campaign ahead of another COVID-19 surge.